Gainers

• Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million.
• Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 38.24% to $3.0. The company's market cap stands at $1.5 million.
• YD Bio (NASDAQ:YDES) stock moved upwards by 26.61% to $4.9. The market value of their outstanding shares is at $274.1 million.
• Modular Medical (NASDAQ:MODD) stock increased by 9.14% to $3.94. The market value of their outstanding shares is at $29.4 million.
• Regenxbio (NASDAQ:RGNX) stock increased by 8.9% to $10.2. The market value of their outstanding shares is at $618.5 million.
• Calidi Biotherapeutics (AMEX:CLDI) stock moved upwards by 8.46% to $1.41. The market value of their outstanding shares is at $3.3 million.

Losers

• BioXcel Therapeutics (NASDAQ:BTAI) shares declined by 61.8% to $0.27 during Friday's pre-market session. The market value of their outstanding shares is at $22.5 million.
• BioAtla (NASDAQ:BCAB) stock decreased by 47.14% to $1.66. The company's market cap stands at $5.2 million.
• Beyond Air (NASDAQ:XAIR) stock declined by 25.62% to $4.24. The market value of their outstanding shares is at $5.6 million.
• BioLine Rx (NASDAQ:BLRX) shares declined by 19.93% to $2.21. The market value of their outstanding shares is at $12.0 million.
• Propanc Biopharma (NASDAQ:PPCB) shares declined by 15.7% to $1.88. The company's market cap stands at $5.0 million.
• VolitionRX (AMEX:VNRX) shares declined by 11.88% to $0.44. The market value of their outstanding shares is at $7.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.